IN2014DN09571A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09571A
IN2014DN09571A IN9571DEN2014A IN2014DN09571A IN 2014DN09571 A IN2014DN09571 A IN 2014DN09571A IN 9571DEN2014 A IN9571DEN2014 A IN 9571DEN2014A IN 2014DN09571 A IN2014DN09571 A IN 2014DN09571A
Authority
IN
India
Prior art keywords
agonist
active ingredients
pharmaceutical formulation
special
constituent
Prior art date
Application number
Other languages
English (en)
Inventor
John Bondo Hansen
Mikael S Thomsen
Jens D Mikkelsen
Peter Gudmund Nielsen
Mads Kreilgaard
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2012/050190 external-priority patent/WO2012163365A1/en
Application filed by Contera Pharma Aps filed Critical Contera Pharma Aps
Publication of IN2014DN09571A publication Critical patent/IN2014DN09571A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9571DEN2014 2012-04-18 2013-04-18 IN2014DN09571A (cs)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201270196 2012-04-18
PCT/DK2012/050190 WO2012163365A1 (en) 2011-06-01 2012-06-01 Combinations of serotonin receptor agonists for treatment of movement disorders
DKPA201270755 2012-12-04
PCT/DK2013/050111 WO2013156035A1 (en) 2012-04-18 2013-04-18 Orally available pharmaceutical formulation suitable for improved management of movement disorders

Publications (1)

Publication Number Publication Date
IN2014DN09571A true IN2014DN09571A (cs) 2015-07-17

Family

ID=49382938

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9571DEN2014 IN2014DN09571A (cs) 2012-04-18 2013-04-18

Country Status (23)

Country Link
US (1) US10561618B2 (cs)
EP (1) EP2838517B1 (cs)
JP (1) JP6216768B2 (cs)
KR (1) KR102104635B1 (cs)
CN (1) CN104411301B (cs)
AU (1) AU2013248685B2 (cs)
BR (1) BR112014025907B1 (cs)
CA (1) CA2870123C (cs)
DK (1) DK2838517T3 (cs)
ES (1) ES2654787T3 (cs)
HU (1) HUE037732T2 (cs)
IL (1) IL235000B (cs)
IN (1) IN2014DN09571A (cs)
MX (1) MX361372B (cs)
MY (1) MY169068A (cs)
NO (1) NO2838517T3 (cs)
NZ (1) NZ700474A (cs)
PH (1) PH12014502331B1 (cs)
PL (1) PL2838517T3 (cs)
PT (1) PT2838517T (cs)
RU (1) RU2670272C2 (cs)
SG (1) SG11201406690SA (cs)
WO (1) WO2013156035A1 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950469C (en) * 2014-06-26 2022-09-20 Contera Pharma Aps Use of buspirone metabolites
MX374938B (es) * 2014-07-09 2025-03-06 Pf Medicament Un método para el tratamiento de trastornos del movimiento con befiradol.
BR112017015487A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
MX2019014272A (es) 2017-06-01 2020-12-11 Xoc Pharmaceuticals Inc Compuestos policiclicos y usos de los mismos.
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
US10758535B1 (en) * 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
US11559525B2 (en) 2019-04-26 2023-01-24 Sumitomo Pharma Co., Ltd. Therapeutic drug for dyskinesia
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
JPWO2022045336A1 (cs) 2020-08-31 2022-03-03
IL307194A (en) * 2021-03-25 2023-11-01 Maplight Therapeutics Inc Pharmaceutical compositions comprising zolmitriptan
WO2025164698A1 (ja) * 2024-01-31 2025-08-07 株式会社ケイファーマ ハンチントン病治療剤及び治療用組成物
CN118308475B (zh) * 2024-03-18 2024-11-26 安徽医科大学第一附属医院 Htr1b作为胚胎发育停滞的诊断标志物和治疗靶点方面的应用
EP4647069A1 (en) 2024-05-07 2025-11-12 Universita' Degli Studi Di Trieste Drugs and compositions for use in the treatment of rett syndrome

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
JP2738461B2 (ja) 1990-06-07 1998-04-08 ザ・ウエルカム・ファウンデーション・リミテッド 治療用複素環化合物
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
ATE374192T1 (de) 2000-11-29 2007-10-15 Lilly Co Eli 1-(2-m-methansulfonamidophenylethyl)-4-(m- trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
AU2002241565A1 (en) 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
AU2002355686B2 (en) * 2001-07-04 2007-11-29 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
KR100912911B1 (ko) * 2001-09-19 2009-08-20 메르크 파텐트 게엠베하 치환된 아미노메틸 크로만의 신규한 용도
WO2005034908A2 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
EP1711493A2 (en) 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
BRPI0514983A (pt) 2004-09-07 2008-07-01 Pfizer combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
KR20070087678A (ko) * 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
AU2006206718B2 (en) * 2005-01-18 2011-06-02 Merck Sharp & Dohme Corp. CGRP receptor antagonists
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
AU2007249435A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007144422A2 (en) 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
US20080069874A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
WO2008047839A1 (en) 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. 5-ht1a receptor agonist
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
US20110183995A1 (en) 2008-06-24 2011-07-28 Neurosearch A/S Eltoprazine for suppression of l-dopa induced dyskinesias
RU2011119494A (ru) 2008-10-14 2012-11-27 Макнейл Аб Многокомпонентная интраоральная лекарственная форма препарата и ее применение
JP5723787B2 (ja) 2009-01-23 2015-05-27 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 制御放出の製剤処方または食品処方およびその製造方法
WO2011079313A1 (en) 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
SI2627328T1 (sl) 2010-10-15 2017-01-31 Contera Pharma Aps Kombinacije agonistov receptorjev serotonina za zdravljenje motenj premikanja
WO2012163365A1 (en) 2011-06-01 2012-12-06 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders

Also Published As

Publication number Publication date
PT2838517T (pt) 2018-01-04
AU2013248685A1 (en) 2014-10-16
US20150104506A1 (en) 2015-04-16
EP2838517B1 (en) 2017-10-18
JP2015514727A (ja) 2015-05-21
IL235000B (en) 2018-01-31
MX2014012408A (es) 2014-12-10
EP2838517A1 (en) 2015-02-25
WO2013156035A1 (en) 2013-10-24
US10561618B2 (en) 2020-02-18
MY169068A (en) 2019-02-12
AU2013248685B2 (en) 2017-07-27
NO2838517T3 (cs) 2018-03-17
CN104411301B (zh) 2018-02-06
CA2870123A1 (en) 2013-10-24
NZ700474A (en) 2016-10-28
ES2654787T3 (es) 2018-02-15
PH12014502331A1 (en) 2014-12-22
SG11201406690SA (en) 2014-11-27
BR112014025907A2 (pt) 2017-06-20
KR102104635B1 (ko) 2020-04-27
MX361372B (es) 2018-12-05
PL2838517T3 (pl) 2018-03-30
RU2670272C2 (ru) 2018-10-22
CA2870123C (en) 2021-02-23
DK2838517T3 (en) 2018-01-15
HUE037732T2 (hu) 2018-09-28
RU2014145944A (ru) 2016-06-10
CN104411301A (zh) 2015-03-11
HK1207285A1 (en) 2016-01-29
BR112014025907B1 (pt) 2023-02-14
JP6216768B2 (ja) 2017-10-18
KR20140146207A (ko) 2014-12-24
PH12014502331B1 (en) 2019-08-23

Similar Documents

Publication Publication Date Title
IN2014DN09571A (cs)
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
PH12015501247A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
EE05760B1 (et) Ravimkoostis
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
PH12017501736B1 (en) Indole derivatives
JP2015520154A5 (cs)
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity